Dyne Therapeutics (DYN) shares were up 1.7% in early trading Thursday after the company reported a Q4 net loss of $0.88 per diluted share, compared with a $1.09 loss a year earlier.
Analysts polled by FactSet expected a $0.94 loss.
The company did not report revenue for the quarter ended Dec. 31.
The company said it had $642.3 million in cash, cash equivalents and marketable securities as of Dec. 31, which together with about $140.6 million in net proceeds from a recent at-the-market offering is expected to fund operations at least into H2 of 2026.
Price: 14.03, Change: +0.24, Percent Change: +1.74
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。